Company intelligence / Profile preview

Adtech Pharma

California, United States

Ownership: Private
Development stage: Other

Overview

Adtech Pharma is developing a novel synthetic cannabinoid ophthalmic formulation aimed at lowering intraocular pressure in glaucoma; available public information describes it as a preclinical-stage program with no reported human clinical results yet.[1][2][4][5][6]

Therapeutic areas: Ophthalmology
Modalities: Small moleculeSynthetic cannabinoid
Industry: Biotech

Drug pipeline

1 asset

NB-110

Preclinical

Partnerships

Ault Global Holdings (now BitNile Holdings / related entities)

Beyond the preview

Go deeper on Adtech Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adtech Pharma.

Explore the full profile